Pelthos Therapeutics Inc. (PTHS) is a Healthcare · Biotechnology company listed on NYSE MKT. Price $22.41 (+0.13%), Market cap $0.09B, 52-week low–high $0.93 ~ $37.42.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older; and XEGLYZE, a pediculicide indicated for topical treatment of head lice infestation in patients 6 months of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly kn
Financial statements, price targets, institutional (13F) holdings and related news for Pelthos Therapeutics Inc. are updated in real time on BlackAll Trade.
Pelthos Therapeutics Inc. trades at $22.41 (+0.13%). Real-time quotes and charts are available on BlackAll Trade.
Pelthos Therapeutics Inc. has a market cap of about $0.09B.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment o